Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 353

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Open access
Maury, Sébastien, Chevret, Sylvie, Thomas, Xavier, Heim, Dominik, Leguay, Thibaut, Huguet, Françoise, Chevallier, Patrice, Hunault, Mathilde, Boissel, Nicolas, Escoffre-Barbe, Martine, Hess, Urs, Vey, Norbert, Pignon, Jean-Michel, Braun, Thorsten, Marolleau, Jean-Pierre, Cahn, Jean-Yves, Chalandon, Yves, Lhéritier, Véronique, Beldjord, Kheira, Béné, Marie C., Ifrah, Norbert, Dombret, Hervé·2016·New England Journal of Medicine
DOI 10.1056/nejmoa1605085
Open this paper in CoChat — free account

Abstract

BACKGROUND: Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial. METHODS: We randomly assigned adults (18 to 59 years of age) with CD20-positive, Philadelphia chromosome (Ph)-negative ALL to receive chemotherapy with or without rituximab, with event-free survival as the primary end point. Rituximab was given during all treatment phases, for a total of 16 to 18 infusions. RESULTS: From May 2006 through April 2014, a total of 209 patients were enrolled: 105 in the rituximab group and 104 in the control group. After a median follow-up of 30 months, event-free survival was longer in the rituximab group than in the control group (hazard ratio, 0.66; 95% confidence interval [CI], 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) and 52% (95% CI, 43 to 63), respectively. Treatment with rituximab remained associated with longer event-free survival in a multivariate analysis. The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. CONCLUSIONS: Adding rituximab to the ALL chemotherapy protocol improved the outcome for younger adults with CD20-positive, Ph-negative ALL. (Funded by the Regional Clinical Research Office, Paris, and others; ClinicalTrials.gov number, NCT00327678 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1605085

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 353

Metadata

Authors
Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., Chevallier, P., Hunault, M., Boissel, N., Escoffre-Barbe, M., Hess, U., Vey, N., Pignon, J.-M., Braun, T., Marolleau, J.-P., Cahn, J.-Y., Chalandon, Y., Lhéritier, V., Beldjord, K., Béné, M. C., Ifrah, N., & Dombret, H.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2016-09-15
Volume
375
Issue
11
Pages
1044-1053
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1605085
OpenAlex
W2520695016
Cited by
353
References
22
FWCI
40.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1056/nejmoa1605085
The paper
Maury, S., Chevret, S., Thomas, X., Heim, D., Leguay, T., Huguet, F., Chevallier, P., Hunault, M., Boissel, N., Escoffre-Barbe, M., Hess, U., Vey, N., Pignon, J.-M., Braun, T., Marolleau, J.-P., Cahn, J.-Y., Chalandon, Y., Lhéritier, V., Beldjord, K., . . . Dombret, H. (2016). Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1605085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.